机构：[1]the Third AffiliatedHospital of SUN YAT-SEN University, Guangzhou, China[2]the First AffiliatedHospital of Xiamen University, Xiamen, China[3]QILU Hospital of ShandongUniversity, Shandong, China[4]Guangdong Province Traditional Chinese MedicalHospital, Guangzhou, China[5]the First Affiliated Hospital of SOOCHOW University,Suzhou, China[6]Linyi City People Hospital, Shandong, China
第一作者机构：[1]the Third AffiliatedHospital of SUN YAT-SEN University, Guangzhou, China
推荐引用方式(GB/T 7714)：
Tu Liudan,Wei Qiujing,Xie Ya,et al.BIOSIMILAR BAT1406 VERSUS ADALIMUMAB THERAPY ON ACTIVE ANKYLOSING SPONDYLITIS: A RANDOMIZED, DOUBLE-BLINDED, MULTICENTER, CONTROLLED PHASE 3 TRIAL[J].ANNALS OF THE RHEUMATIC DISEASES.2019,78:895-895.doi:10.1136/annrheumdis-2019-eular.4455.
APA：
Tu, Liudan,Wei, Qiujing,Xie, Ya,Shi, Guixiu,Liu, Huaxiang...&Gu, Jieruo.(2019).BIOSIMILAR BAT1406 VERSUS ADALIMUMAB THERAPY ON ACTIVE ANKYLOSING SPONDYLITIS: A RANDOMIZED, DOUBLE-BLINDED, MULTICENTER, CONTROLLED PHASE 3 TRIAL.ANNALS OF THE RHEUMATIC DISEASES,78,
MLA：
Tu, Liudan,et al."BIOSIMILAR BAT1406 VERSUS ADALIMUMAB THERAPY ON ACTIVE ANKYLOSING SPONDYLITIS: A RANDOMIZED, DOUBLE-BLINDED, MULTICENTER, CONTROLLED PHASE 3 TRIAL".ANNALS OF THE RHEUMATIC DISEASES 78.(2019):895-895
医学